Aniara Diagnostica, Inc. showcases Hyphen BioMed’s Lysis Timer at ISTH 2025

NEWS PROVIDED BY
Aniara Diagnostica, Inc.
June 18, 2025

Aniara Diagnostica, Inc. will spotlight the Lysis Timer (ALT-8V), a handheld device optimized by Hyphen BioMed to evaluate Global Fibrinolytic Capacity (GFC) in citrated plasma, during ISTH 2025.  The Lysis Timer, designed for research use only, represents a key advancement in the study of fibrinolysis by simply providing fast and reliable results.

For Research Use Only. Not for Use in Diagnostic Procedures.

WEST CHESTER, Ohio, June 18, 2025 -- Aniara Diagnostica, Inc., a multi-national distributor of diagnostic and research reagents, as well as screening tools, has strengthened its commitment to meeting today's highest standards for product quality and cost-efficient delivery.

The Lysis Timer is a semi-automated handheld device for the study of euglobulin lysis time (or analysis of clot dissolution kinetics resulting from thrombin coagulation) in a sample of citrated human plasma in the presence of human tPA (recombinant) and silica (tPA-silica solution). The device provides results in less than 1 hour using a low sample volume of 100μL. Intended for use in research settings, the Lysis Timer offers a reliable tool for evaluating fibrinolytic function.

To learn more about the utility of the Lysis Timer, we invite you to stop by the Aniara Diagnostica, Inc. booth #620 for more hands-on and in-depth product information.

The entire Aniara line is available for purchase at http://www.aniara.com.

ALT-8V Lysis Timer click here for more information
ALT-CV Glass Tubes click here for more information
ACK093K GFC Test click here for more information
ASC104K GFC Control Plasmas click here for more information

Aniara Diagnostica, Inc. distributes products in North America, Sweden, Norway, Denmark, Finland, Lithuania, Latvia, Estonia and Iceland.

Media Contact

Janey Atkinson, Aniara Diagnostica, Inc., jatkinson@aniara.com, www.aniara.com

SOURCE Aniara Diagnostica, Inc.

Previous Article Remembering Gerhard Johnson
Next Article Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025